This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Oncology  • Skin Cancer  • Ophthalmology  • Ophthalmological Disorders  • External Eye Disease  • Ocular/ Adnexal Tumors  • Dermatology  • Dermatologic Disorders  • Neoplasms  • Drug Therapy  • Drug Therapy, Other  • Alert me on articles by topic  Social Bookmarking   What's this?

Katrine Togsverd-Bo, MD; Merete Hædersdal, MD, DSc, PhD; Hans Christian Wulf, MD, DSc

Arch Dermatol. 2009;145(8):944-947.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

The eyelids are prone to basal cell carcinomas (BCCs) and papillomas.¹ Cryotherapy, surgical excision, and radiotherapy have limitations related to their complexity and to the resulting functional deficiencies (eg, lagophthalmos or epiphora) and unsatisfying cosmesis.² New treatment techniques for eyelid tumors are therefore desirable.

Photodynamic therapy (PDT) with topical methyl aminolevulinate (Metvix cream, 16%; Photocure ASA, Oslo, Norway) is a safe and effective noninvasive treatment of BCCs that causes minimal damage to surrounding tissue and results in excellent cosmetic outcomes.³ However, PDT is not normally used to treat eyelid lesions owing to the risk of phototoxic eye damage. We describe how PDT can be performed safely in the treatment of eyelid BCC and papilloma in unselected cases.

Methods

Conjunctival anesthetic is administered (oxybuprocaine, 0.4%), and an ocular shield is inserted. Infiltration anesthetic (carbocaine, 20%, with adrenalin, 5%) is . . . [Full Text of this Article]

Results

Comment

AUTHOR INFORMATION


CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?